Difference between revisions of "Profiles"
Jump to navigation
Jump to search
m |
m |
||
| Line 18: | Line 18: | ||
'''''Public Comment closed''''' | '''''Public Comment closed''''' | ||
| − | |||
*[[Media:001.QIBA SPECT Profile.v0.1 2016.10.28.docx | Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease Profile (v1.0), October 28, 2016]] (''Public Comment ended Feb 2017'') | *[[Media:001.QIBA SPECT Profile.v0.1 2016.10.28.docx | Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease Profile (v1.0), October 28, 2016]] (''Public Comment ended Feb 2017'') | ||
:*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|Checklist: SPECT Profile Conformance]] | :*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|Checklist: SPECT Profile Conformance]] | ||
| Line 24: | Line 23: | ||
*[[Media:QIBA_CT_Vol_LungNoduleAssessmentInCTScreening_v5-2-16b.docx|QIBA Profile: QIBA Profile: Lung Nodule Volume Assessment and Monitoring in Low Dose CT Screening, June 1, 2016]] (''Public Comment ended Sept 2016'') | *[[Media:QIBA_CT_Vol_LungNoduleAssessmentInCTScreening_v5-2-16b.docx|QIBA Profile: QIBA Profile: Lung Nodule Volume Assessment and Monitoring in Low Dose CT Screening, June 1, 2016]] (''Public Comment ended Sept 2016'') | ||
| − | *[[Media:QIBA Small Nodule Profile References - Accuracy.xlsx|QIBA Spreadsheet: Small Nodule Profile References_Accuracy. Version for Public Comment. June 1, 2016]] | + | :*[[Media:QIBA Small Nodule Profile References - Accuracy.xlsx|QIBA Spreadsheet: Small Nodule Profile References_Accuracy. Version for Public Comment. June 1, 2016]] |
| − | *[[Media:QIBA Small Nodule Profile References - Precision.xlsx|QIBA Spreadsheet: Small Nodule Profile References_Precision. Version for Public Comment. June 1, 2016]] | + | :*[[Media:QIBA Small Nodule Profile References - Precision.xlsx|QIBA Spreadsheet: Small Nodule Profile References_Precision. Version for Public Comment. June 1, 2016]] |
| + | * [[Media:DCEMRIProfile v1 6-20111213.pdf|DCE-MRI Quantification 2011-12-13]] (''Public Comment ended Feb 2012'') | ||
==Statements of Endorsement== | ==Statements of Endorsement== | ||
Revision as of 23:15, 23 June 2017
Profiles published here have completed one of the QIBA Profile Stages of development and been approved by their Biomarker Committee.
Stage 3: Technically Confirmed Profiles
Stage 2: Consensus Profiles
Stage 1: Public Comment Profiles
Link to QIBA Public Comment Form: http://tinyurl.com/y8dy2pc2
- QIBA fMRI Profile 2017-06-19 Public Comment to open on June 19, 2017
- QIBA PET Amyloid Profile 2017-06-15 Public Comment is open until September 15, 2017
- DWI Profile 2017-04-27 Public Comment is open until July 28, 2017
Public Comment closed
- Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease Profile (v1.0), October 28, 2016 (Public Comment ended Feb 2017)
- QIBA Profile: QIBA Profile: Lung Nodule Volume Assessment and Monitoring in Low Dose CT Screening, June 1, 2016 (Public Comment ended Sept 2016)
- DCE-MRI Quantification 2011-12-13 (Public Comment ended Feb 2012)
Statements of Endorsement
See Also
- How to use QIBA Profiles
- Biomarker Committee pages may also have links to DRAFT Profile documents for the next Stage.
- Profile Conformance describes how sites and products claim conformance to a Profile.
- QIBA Profile Template shows the structure, rationale and content of a Profile (show "All Markup" to see guidance in the Word comments)